CFO
RPRX icon

Callan Family Office’s Royalty Pharma RPRX Stock Holding History

Callan Family Office’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$570K Sell
11,876
-1,496
-11% -$65.5K 0.01% 724
2025
Q4 		$517K Buy
+13,372
New +$510K 0.01% 778
2025
Q3 		– Sell
-16,418
Closed -$592K – 931
2025
Q2 		$592K Buy
+16,418
New +$544K 0.02% 537

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Callan Family Office's RPRX Position: Q1 2026 in Review

Callan Family Office reduced its Royalty Pharma (RPRX) stake by 11% in Q1 2026, selling an estimated $65.5K and leaving 11,876 shares worth $570K. The position accounts for 0.01% of the portfolio, ranked #724.

Callan Family Office first reported a position in RPRX in Q2 2025 and has held it in 3 quarters since. The position peaked at $592K in Q2 2025. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Callan Family Office held 11,876 shares of Royalty Pharma worth $570K as of Q1 2026.
  • Callan Family Office sold 1,496 Royalty Pharma shares in Q1 2026, an estimated $65.5K.
  • Royalty Pharma made up 0.01% of Callan Family Office's portfolio in Q1 2026, its #724 holding.
  • Callan Family Office first reported a position in Royalty Pharma in Q2 2025 and has held it in 3 quarters since.
  • Callan Family Office's Royalty Pharma position peaked at $592K in Q2 2025.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.